Not yet recruiting
Neoplasm
Not yet recruitingStudy of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer
Registered drugNo placebo
Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer
Registered drugNo placebo
- Disease:Neoplasm
- Substances:DurvalumabIDE-161+1
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Durvalumab

